AstraZeneca: Fasenra Met Co-Primary Endpoints in OSTRO Phase 3 Trial
By Anthony O. Goriainoff
AstraZeneca PLC said Thursday that Fasenra met both co-primary
endpoints in the OSTRO Phase 3 trial for patients with chronic
rhinosinusitis with nasal polyps.
Fasenra--a treatment for severe eosinophilic asthma--showed a
significant improvement in the size of nasal polyps and in nasal
blockage in patients, the company said.
The FTSE 100-listed drug maker said Fasenra demonstrated a
statistically significant improvement in the endoscopic total nasal
polyp score and the nasal blockage score compared with placebo in
patients with severe bilateral nasal polyposis who were still
symptomatic despite continued treatment with standard of care.
Standard of care consists of intranasal corticosteroids and prior
surgery and/or use of systemic corticosteroids, the company
Eosinophilic asthma is a type of severe asthma usually marked by
high levels of white blood cells.
"Fasenra is currently approved as an add-on maintenance
treatment for severe eosinophilic asthma in the U.S., EU, Japan and
other countries, and is approved for self-administration in the
U.S., EU and other countries," the company said.
Write to Anthony O. Goriainoff at
(END) Dow Jones Newswires
September 10, 2020 02:44 ET (06:44 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
From Dec 2020 to Jan 2021
From Jan 2020 to Jan 2021